7 articles reveal the many health risks faced by people living with HIV! From the largest AIDS co-existence disease research in history!

!--Webeditor:page title" -- A series of recent articles published by Journal of The Journal of The Disease reveal the impact and prevalence of heart disease and other severe complications on an aging global population with human immunodeficiency virus (HIV), including important data from the largest study of cardiovascular disease in HIV patients worldwideThis information comes from an ongoing national health research funded by the National Institutes of Health (NIH) called REPRIEVE (Random Trial to Prevent Vascular Events in HIV), in which MGH plays a key coordinating roleThis information helps the medical community anticipate the disproportionate risk of complications such as cardiovascular disease, chronic liver and kidney disease, physical dysfunction and vulnerability, premature reproductive aging, cancer, and obesity in HIV patients worldwide"Nearly half of people living with HIV are now over 50 years of ageThe focus of health care providers has shifted over the past 20 years from life-sustaining antiretroviral therapy to providing the best care for patients with secondary combined conditions to significantly increase longevitySteven Grinspoon, co-co-co-coordinator of REPRIEVE and director of the MGH Metabolic Unit and a professor of medicine at Harvard Medical School, said"Initial baseline data from REPRIEVE will help doctors and researchers better understand the impact of HIV on the population as a whole and ultimately develop more effective prevention, treatment strategies and guidelines for cardiovascular risk management in this population." Secondary cocombinal disease is becoming the latest frontier of HIV in a very real wayPhoto: NIAID, funded by the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID), REPRIEVE enrolled 7,770 patients from 12 countries and five continents who participated in more than 100 clinical studies from 2015 to 2019, reflecting the national, racial and gender diversity of the global AIDS epidemicThis high-profile global collaboration, including the AIDS Clinical Trials Group and the pharmaceutical industry, is expected to report its findings to the public in 2023Last year, NIAID Director DrAnthony Fauci and colleagues cited the study in JAMA,they say it is critical to uncover the mechanisms and potential treatments for ischemic heart disease and other severe cardiovascular diseases in HIV carriersMassachusetts General Hospital is rePRIEVE's clinical focal point and coordinates data collection for the trial with the Harvard School of Public HealthThis responsibility includes continuous evaluation of coronary atherosclerosis in 30 locations across the United States using the latest noninvasive CT angioplasty technology"Specific pattern imaging of coronary artery disease will help us better analyze cardiovascular risk in people with REPRIEVE," explained Udo Hoffmann, co-lead researcher, professor of radiology, M.D., and master of public health at Harvard Medical School and REPRIEVEOne of THE MAIN GOALS OF REPRIEVE IS TO REDUCE THE MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE LIVING WITH HIV THROUGH HEART PREVENTION STRATEGIES, WHILE ALSO ASSESSING NON-CVD CO-EXISTING DISEASESThe six articles published in Journal of The Journal of The Journal are the data features of the first version of the studyFor example, an article reported that physical dysfunction and pre-debilitating are common in middle-aged people living with HIV, while body mass index (BMI) and physical activity are key variable risk factors that may prevent further decline in the body function of this population with age Another paper suggests that reproductive aging in middle-aged women living with HIV is associated with the Global Burden of Disease (GBD) in registered areas and may increase the risk of heart metabolism in these women The paper also illustrates the unique associations between different patterns of antiretroviral drug use, weight and immune function worldwide, as well as factors in people living with HIV that contribute to increased renal dysfunction and increased cardiac ectopic fat deposits New data on the participation of transgender participants and the cardiovascular riskassociats associated with gender-recognized treatment have also been reported "The initial data compilation window for this landmark REPRIEVE study provides doctors with a wealth of information on a variety of diseases Doctors have found that the HIV population is changing as a result of effective antiretroviral drugs, increased life expectancy and a significant increase in cardiovascular and other co-diseases among people who remain vulnerable Grinspoon said "By first raising awareness of the magnitude and complexity of the problem, we believe this information and further information will play a key role in developing heart prevention strategies and improving health care for 37 million people living with HIV worldwide." References: Study highlights multiple health risks a people people longer living with HIVTomas G Neilan et al, Myocardial Steatosis Trans Of therapy-Treated People With Human Eire Virus SinReReReVe, The Journal of The Journal of The Disease (2020) DOI: 10.1093/indix/jiaa245ing a.!-- !-- a The Good About the Virgin Sinaar s Middle-Aged People Living With Human Immunoy Virus in the REPRIEVE Trial Study R R Riti PREPARE !--/ewebeditor:page.